Overview
Newron Pharmaceuticals S.p.A. is a biopharmaceutical company based in Italy, primarily engaged in the research and development of novel therapies for diseases of the central and peripheral nervous system. The firm's flagship product is Xadago/Safinamide, a treatment for Parkinson's disease that has been launched in multiple countries. Newron is also advancing a robust pipeline of promising projects, including Evenamide, a novel treatment for schizophrenia currently in Phase III trials, and Sarizotan, a treatment for Rett syndrome in late-stage development.
AI+ Ask Fintel’s AI assistant about Newron Pharmaceuticals S.p.A..
Thinking about good questions…
Basic Stats
The share price of Newron Pharmaceuticals S.p.A. as of 5 September 2025 is CHF 9,31 / share. This is an increase of 9.79% from the prior week.
The Factor Analysis chart (below right) shows a view of Newron Pharmaceuticals S.p.A. from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | 0.00 MM |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | 9.59 |
| Short Shares Avail. | 0.10 MM |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | 18.90 % |
| Volatility (1 yr) | 0.57 |
| Beta | 0.92 |
| Sharpe Ratio (1 yr) | 0.26 |
| Sortino Ratio (1 yr) | 0.51 |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 52.58 /100 |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | 62.10 /100 |
| Stability (Low Vol) Score | 31.83 /100 |
| Analyst Sentiment | 77.46 /100 |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 2.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Newron Pharmaceuticals S.p.A. is CHF 16,76. The forecasts range from a low of CHF 11,62 to a high of CHF 26,25. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Newron Pharmaceuticals S.p.A.. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2023-03-20 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-03-14 | RX SECURITIES | Buy | Buy | Maintains |
| 2020-09-16 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-03-19 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-03-13 | RX SECURITIES | Buy | Buy | Maintains |
| 2023-08-10 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-08-11 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-10-09 | RX SECURITIES | Buy | Buy | Maintains |
| 2024-05-14 | RX SECURITIES | Buy | Buy | Maintains |
| 2024-05-12 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2024-01-03 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2023-10-08 | RX SECURITIES | Buy | Buy | Maintains |
| 2024-12-12 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2025-01-05 | RX SECURITIES | Buy | Buy | Maintains |
| 2025-03-31 | BAADER HELVEA EQUITY RESEARCH | Buy | Buy | Maintains |
| 2025-03-31 | RX SECURITIES | Buy | Buy | Maintains |
| 2025-05-11 | RX SECURITIES | Buy | Buy | Maintains |
